Novartis loses another NIBR exec as neuro expert Shanker joins a gene therapy biotech
by Kyle LaHucik | May 19, 2021 9:55am Another Novartis R&D leader exits the Swiss pharma giant to take on an executive role at a biotech startup. (Pixabay) Novartis' Gopi Shanker, Ph.D., is the latest R&D leader to exit the Swiss pharma giant as he takes up the helm of chief scientific officer at gene therapy startup Tevard Biosciences. Shanker follows the exit of Jeff Engelman M.D., Ph.D., who left the Novartis Institutes for Biomedical Research (NIBR) in late-April to form a new cancer biotech, Treeline Biosciences. Days later, Peter Hammerman, M.D., Ph.D., ...
Source: fiercebiotech.com